7 completed, 2 active not recruiting, 2 recruiting, 1 unknown. 13 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 7, Active not recruiting 2, Recruiting 2, Unknown 1, Withdrawn 1 |
| Phase 2 | 2 | Recruiting 1, Unknown 1 |
Follow Adrenogenital Syndrome: new trials by email Literature Review of Adrenogenital Syndrome trials Research Report on Adrenogenital Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH) Atumelnant, Placebo - Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia | Phase 2 / Phase 3 | Recruiting | Crinetics Pharmaceuticals Inc. | 153 | 2026-01-22 | 2026-10-16 |
| A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia Atumelnant, Placebo - Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia | Phase 3 | Recruiting | Crinetics Pharmaceuticals Inc. | 150 | 2025-12-11 | 2026-10-16 |
| Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia Chronocort, Cortef, Placebo - Congenital Adrenal Hyperplasia | Phase 3 | Completed | Neurocrine UK Limited | 55 | 2022-05-24 | 2026-10-02 |
| Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia Chronocort - Congenital Adrenal Hyperplasia | Phase 3 | Completed | Immedica Pharma AB | 76 | 2022-04-01 | 2026-06-18 |
| Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study) Crinecerfont, Placebo - Congenital Adrenal Hyperplasia | Phase 3 | Active not recruiting | Neurocrine Biosciences | 103 | 2021-06-25 | 2025-02-05 |
| Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia Crinecerfont, Placebo - Congenital Adrenal Hyperplasia | Phase 3 | Active not recruiting | Neurocrine Biosciences | 182 | 2020-12-16 | 2026-05-11 |
| Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy Chronocort®, Standard Care - Congenital Adrenal Hyperplasia | Phase 3 | Withdrawn | Neurocrine UK Limited | 2018-10-04 | 2026-09-14 | |
| A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH Hydrocortisone - Congenital Adrenal Hyperplasia | Phase 3 | Completed | Neurocrine UK Limited | 91 | 2016-08-18 | 2026-10-02 |
| Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia Chronocort®, standard glucocorticoid therapy - Congenital Adrenal Hyperplasia | Phase 3 | Completed | Neurocrine UK Limited | 122 | 2016-02-22 | 2026-10-02 |
| COrticosteroid in Congenital Adrenal Hyperplasia Hormonal balance measurements, metabolic balance measurements, bone balance measurements - Congenital Adrenal Hyperplasia | Phase 2 / Phase 3 | Unknown | University Hospital, Caen | 40 | 2012-08-01 | 2015-09-17 |
| Effect of a Commonly Used Antibiotic, Doxycycline, in Women With Polycystic Ovarian Syndrome doxycycline, Sugar Pill - Polycystic Ovarian Syndrome (PCOS), Irregular Menstrual Cycles | Phase 3 | Completed | University of Rochester | 10 | 2010-11-01 | 2016-01-13 |
| The Effect of Metformin Added to Clomiphene Citrate on Pregnancy Rates in Hyperandrogenic, Chronic Oligoovulatory or Anovulatory Women Metformin, Clomiphene citrate, Placebo - Polycystic Ovary Syndrome, Anovulation | Phase 3 | Completed | 59th Medical Wing | 56 | 1997-12-01 | 2006-12-19 |
| Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia Fludrocortisone, Hydrocortisone, Letrozole - Congenital Adrenal Hyperplasia (CAH) | Phase 3 | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 66 | 1995-06-08 | 2025-06-12 |
Adrenal Hyperplasia, Congenital (11) · Hyperandrogenism (2) · Polycystic Ovary Syndrome (2) · Anovulation (1) · Congenital adrenal hyperplasia due to 21 hydroxylase deficiency (1) · Infertility (1) · Menstruation Disturbances (1)
Congenital Abnormalities (13) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (13) · Disorders of Sex Development (13) · Endocrine System Diseases (13) · Female Urogenital Diseases (13) · Female Urogenital Diseases and Pregnancy Complications (13) · Gonadal Disorders (13) · Male Urogenital Diseases (13) · Urogenital Abnormalities (13) · Urogenital Diseases (13) · Adrenal Gland Diseases (11) · Genetic Diseases, Inborn (11) · Metabolic Diseases (11) · Metabolism, Inborn Errors (11)
Hydrocortisone (5) · Dexamethasone (2) · Prednisolone (2) · Prednisone (2) · crinecerfont (2) · Clomiphene (1) · Doxycycline (1) · Fludrocortisone (1) · Flutamide (1) · Letrozole (1) · Metformin (1) · Standard of Care (1) · Sugars (1) · Testolactone (1)
Neurocrine UK Limited (4) · Crinetics Pharmaceuticals Inc. (2) · Neurocrine Biosciences (2) · 59th Medical Wing (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Immedica Pharma AB (1) · University Hospital, Caen (1) · University of Rochester (1)
United States (12) · France (7) · Germany (4) · Italy (4) · Poland (4) · United Kingdom (4) · Belgium (3) · Canada (3) · Japan (3) · Netherlands (3) · Argentina (2) · Australia (2) · Austria (2) · Brazil (2) · Greece (2)
D Merke (1) · Debbie Merke, MD (1) · Deborah P Merke, M.D. (1) · Kathleen M Hoeger, MD, MPH (1) · Randal D Robinson, MD (1) · Stephen Hammes, MD (1)
PMID 33527139, PMID 38828945, PMID 38828955, PMID 39672600
2023 (2), 2019 (1)